help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clapp, C.
Right arrow Articles by Weiner, R. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clapp, C.
Right arrow Articles by Weiner, R. I.

Endocrinology, Vol 130, 1380-1386, Copyright © 1992 by Endocrine Society


ARTICLES

A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells

C Clapp and RI Weiner
Reproductive Endocrinology Center, University of California, San Francisco 94143.

A 16-kilodalton N-terminal fragment of PRL (16K PRL) is formed by enzymatic cleavage of intact 23-kilodalton PRL (23K PRL) in the pituitary gland and in target tissues for PRL. 16K PRL inhibits the growth of capillary endothelial cells, while intact PRL was inactive suggesting that 16K PRL acted via a receptor other than the PRL receptor. To analyze whether this inhibitory effect could be mediated through an specific 16K PRL receptor, we characterized the binding of 16K PRL to membrane preparations of bovine brain capillary endothelial (BBE) cells. 16K PRL was generated by the proteolysis of rat 23K PRL with a particulate fraction from rat mammary gland homogenates and purified by gel filtration. The specific binding of [125I]16K PRL to BBE cell membranes was high affinity (Kd = 9.9 nM), saturable (Bmax = 4.8 pmol/mg protein), and reversible. In competition studies for [125I]16K PRL binding, 16K PRL was most potent, while little displacement was observed with high concentrations of 23K PRLs, growth hormones, and basic fibroblast growth factor. Blockade of reformation of disulfide bonds by carbamidomethylation of 16K PRL, a procedure which increases the biological activity of the molecule, increased its binding affinity (Kd = 0.9 nM). Cross-linking experiments identified a 52,000 and a 32,000 mol wt protein as the major 16K PRL binding species. These data demonstrate the presence of specific, high affinity, saturable binding sites for 16K PRL on BBE cell membranes and support biological findings that 16K PRL inhibits capillary endothelial cell proliferation, through a novel, high affinity receptor.


This article has been cited by other articles:


Home page
EndocrinologyHome page
M. E. Cruz-Soto, G. Cosio, M. C. Jeziorski, V. Vargas-Barroso, M. B. Aguilar, A. Carabez, P. Berger, P. Saftig, E. Arnold, S. Thebault, et al.
Cathepsin D Is the Primary Protease for the Generation of Adenohypophyseal Vasoinhibins: Cleavage Occurs within the Prolactin Secretory Granules
Endocrinology, December 1, 2009; 150(12): 5446 - 5454.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
C. Clapp, S. Thebault, M. C. Jeziorski, and G. Martinez De La Escalera
Peptide Hormone Regulation of Angiogenesis
Physiol Rev, October 1, 2009; 89(4): 1177 - 1215.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. Clapp, S. Thebault, E. Arnold, C. Garcia, J. C. Rivera, and G. M. de la Escalera
Vasoinhibins: novel inhibitors of ocular angiogenesis
Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E772 - E778.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
N. Ben-Jonathan, C. R. LaPensee, and E. W. LaPensee
What Can We Learn from Rodents about Prolactin in Humans?
Endocr. Rev., February 1, 2008; 29(1): 1 - 41.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S.-H. Lee, J. Kunz, S.-H. Lin, and L.-y. Yu-Lee
16-kDa Prolactin Inhibits Endothelial Cell Migration by Down-Regulating the Ras-Tiam1-Rac1-Pak1 Signaling Pathway
Cancer Res., November 15, 2007; 67(22): 11045 - 11053.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. P. Tabruyn, C. Sabatel, N.-Q.-N. Nguyen, C. Verhaeghe, K. Castermans, L. Malvaux, A. W. Griffioen, J. A. Martial, and I. Struman
The Angiostatic 16K Human Prolactin Overcomes Endothelial Cell Anergy and Promotes Leukocyte Infiltration via Nuclear Factor-{kappa}B Activation
Mol. Endocrinol., June 1, 2007; 21(6): 1422 - 1429.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N.-Q.-N. Nguyen, S. P. Tabruyn, L. Lins, M. Lion, A. M. Cornet, F. Lair, F. Rentier-Delrue, R. Brasseur, J. A. Martial, and I. Struman
Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis
PNAS, September 26, 2006; 103(39): 14319 - 14324.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
Y. Macotela, M. B. Aguilar, J. Guzman-Morales, J. C. Rivera, C. Zermeno, F. Lopez-Barrera, G. Nava, C. Lavalle, G. M. de la Escalera, and C. Clapp
Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin
J. Cell Sci., May 1, 2006; 119(9): 1790 - 1800.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
E. Ueda, U. Ozerdem, Y.-H. Chen, M. Yao, K. T. Huang, H. Sun, M. Martins-Green, P. Bartolini, and A. M Walker
A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 95 - 111.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S.-h. Lee, M. Nishino, T. Mazumdar, G. E. Garcia, M. Galfione, F. L. Lee, C. L. Lee, A. Liang, J. Kim, L. Feng, et al.
16-kDa Prolactin Down-Regulates Inducible Nitric Oxide Synthase Expression through Inhibition of the Signal Transducer and Activator of Transcription 1/IFN Regulatory Factor-1 Pathway
Cancer Res., September 1, 2005; 65(17): 7984 - 7992.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. P. Tabruyn, N.-Q.-N. Nguyen, A. M. Cornet, J. A. Martial, and I. Struman
The Antiangiogenic Factor, 16-kDa Human Prolactin, Induces Endothelial Cell Cycle Arrest by Acting at Both the G0-G1 and the G2-M Phases
Mol. Endocrinol., July 1, 2005; 19(7): 1932 - 1942.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. Gonzalez, A. M. Corbacho, J. P. Eiserich, C. Garcia, F. Lopez-Barrera, V. Morales-Tlalpan, A. Barajas-Espinosa, M. Diaz-Munoz, R. Rubio, S.-H. Lin, et al.
16K-Prolactin Inhibits Activation of Endothelial Nitric Oxide Synthase, Intracellular Calcium Mobilization, and Endothelium-Dependent Vasorelaxation
Endocrinology, December 1, 2004; 145(12): 5714 - 5722.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
D. Piwnica, P. Touraine, I. Struman, S. Tabruyn, G. Bolbach, C. Clapp, J. A. Martial, P. A. Kelly, and V. Goffin
Cathepsin D Processes Human Prolactin into Multiple 16K-Like N-Terminal Fragments: Study of Their Antiangiogenic Properties and Physiological Relevance
Mol. Endocrinol., October 1, 2004; 18(10): 2522 - 2542.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass
Angiogenesis in Endocrine Tumors
Endocr. Rev., October 1, 2003; 24(5): 600 - 632.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. P. Tabruyn, C. M. Sorlet, F. Rentier-Delrue, V. Bours, R. I. Weiner, J. A. Martial, and I. Struman
The Antiangiogenic Factor 16K Human Prolactin Induces Caspase-Dependent Apoptosis by a Mechanism that Requires Activation of Nuclear Factor-{kappa}B
Mol. Endocrinol., September 1, 2003; 17(9): 1815 - 1823.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
C. V. Clevenger, P. A. Furth, S. E. Hankinson, and L. A. Schuler
The Role of Prolactin in Mammary Carcinoma
Endocr. Rev., February 1, 2003; 24(1): 1 - 27.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Kim, W. Luo, D.-T. Chen, K. Earley, J. Tunstead, L.-Y. Yu-Lee, and S.-H. Lin
Antitumor Activity of the 16-kDa Prolactin Fragment in Prostate Cancer
Cancer Res., January 15, 2003; 63(2): 386 - 393.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Bentzien, I. Struman, J.-F. Martini, J. Martial, and R. Weiner
Expression of the Antiangiogenic Factor 16K hPRL in Human HCT116 Colon Cancer Cells Inhibits Tumor Growth in Rag1-/- Mice
Cancer Res., October 1, 2001; 61(19): 7356 - 7362.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
A. Ochoa, P. Montes de Oca, J. C. Rivera, Z. Dueñas, G. Nava, G. M. de la Escalera, and C. Clapp
Expression of Prolactin Gene and Secretion of Prolactin by Rat Retinal Capillary Endothelial Cells
Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1639 - 1645.
[Abstract] [Full Text]


Home page
Mol. Endocrinol.Home page
J.-F. Martini, C. Piot, L. M. Humeau, I. Struman, J. A. Martial, and R. I. Weiner
The Antiangiogenic Factor 16K PRL Induces Programmed Cell Death in Endothelial Cells by Caspase Activation
Mol. Endocrinol., October 1, 2000; 14(10): 1536 - 1549.
[Abstract] [Full Text]


Home page
Physiol. Rev.Home page
M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy
Prolactin: Structure, Function, and Regulation of Secretion
Physiol Rev, October 1, 2000; 80(4): 1523 - 1631.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. M. Corbacho, G. Nava, J. P. Eiserich, G. Noris, Y. Macotela, I. Struman, G. Martinez de la Escalera, B. A. Freeman, and C. Clapp
Proteolytic Cleavage Confers Nitric Oxide Synthase Inducing Activity upon Prolactin
J. Biol. Chem., April 28, 2000; 275(18): 13183 - 13186.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
Z. Duenas, L. Torner, A. M. Corbacho, A. Ochoa, G. Gutierrez-Ospina, F. Lopez-Barrera, F. A. Barrios, P. Berger, Gonzalo Martinez de la Escalera, and C. Carmen
Inhibition of Rat Corneal Angiogenesis by 16-kDa Prolactin and by Endogenous Prolactin-like Molecules
Invest. Ophthalmol. Vis. Sci., October 1, 1999; 40(11): 2498 - 2505.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
G. D’Angelo, J.-F. Martini, T. Iiri, W. J. Fantl, J. Martial, and R. I. Weiner
16K Human Prolactin Inhibits Vascular Endothelial Growth Factor-Induced Activation of Ras in Capillary Endothelial Cells
Mol. Endocrinol., May 1, 1999; 13(5): 692 - 704.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
I. Struman, F. Bentzien, H. Lee, V. Mainfroid, G. D'Angelo, V. Goffin, R. I. Weiner, and J. A. Martial
Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: An efficient mechanism for the regulation of angiogenesis
PNAS, February 16, 1999; 96(4): 1246 - 1251.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. L. Boguszewski, P.-A. Svensson, T. Jansson, R. Clark, L. M. S. Carlsson, and B. Carlsson
Cloning of Two Novel Growth Hormone Transcripts Expressed in Human Placenta
J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2878 - 2885.
[Abstract] [Full Text]


Home page
LupusHome page
I Krause, Z Blumenfeld, M Malchinsky, S Cohen, M Blank, A Eldor, B Weksler, K Schweitzer, and Y Shoenfeld
Anti-endothelial cell antibodies in the sera of hyperprolactinemic women
Lupus, July 1, 1998; 7(6): 377 - 382.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. L. Jones, H. O. D. Critchley, J. Brooks, H. N. Jabbour, and A. S. McNeilly
Localization and Temporal Expression of Prolactin Receptor in Human Endometrium
J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 258 - 262.
[Abstract] [Full Text]


Home page
ScienceHome page
D Jackson, O. Volpert, N Bouck, and D. Linzer
Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein
Science, December 2, 1994; 266(5190): 1581 - 1584.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society